How Specialized Parkinson's Home Care Improves Daily Living
Parkinson's disease is a progressive neurological condition that affects movement, balance, and coordination. As the disease advances, daily activities that once felt routine—such as walking, eating, or getting dressed—can become difficult and even dangerous. While family members often try to help, the increasing demands of care may require professional support. Specialized home care tailored for individuals with Parkinson's offers critical physical, emotional, and cognitive assistance, helping improve daily living and quality of life.
In this article, we'll explore how Parkinson's home care works, its benefits, and how trusted providers like Visiting Angels Manassas support families across Prince William County and surrounding areas.
Parkinson's disease primarily affects motor function, resulting in symptoms such as tremors, muscle stiffness, slowness of movement (bradykinesia), and impaired balance. These symptoms often interfere with simple daily tasks like writing, using utensils, or getting out of a chair. As the condition progresses, walking becomes more difficult and falls more likely.
However, Parkinson's is not just a physical condition. Non-motor symptoms such as depression, sleep disturbances, fatigue, and cognitive decline can be just as challenging. Over time, these symptoms can diminish confidence and increase dependency on others for daily support.
This combination of physical and emotional impact often leads families to seek long-term solutions that maintain safety and well-being at home.
One of the most significant benefits of specialized home care is assistance with mobility and physical safety. Individuals with Parkinson's often experience unsteadiness, slower reflexes, and difficulties with balance. This greatly increases the risk of falls, which can lead to serious injuries.
Professional caregivers trained in Parkinson's care know how to assist with transferring from bed to chair, walking around the house, and using assistive devices properly. They are also skilled in spotting mobility-related hazards and suggesting modifications like grab bars, shower benches, or the removal of clutter.
For families seeking Parkinson's care in Manassas these services provide critical support in maintaining independence while minimizing physical risks.
Proper medication management is vital for those living with Parkinson's. Medications like Levodopa must be taken at specific times to manage symptoms effectively. A missed or late dose can quickly result in loss of motor control or increased stiffness.
Home caregivers ensure medications are taken on schedule and watch for any adverse effects or symptom changes. They also assist with daily routines such as eating, bathing, grooming, and dressing, tasks that become more complex as the disease progresses.
The consistency and reliability of professional care allow individuals to maintain a sense of control and routine, which is especially important for people with Parkinson's who thrive on structure.
For families in Prince William County and surrounding communities, Visiting Angels Manassas is a trusted provider of in-home care services for seniors with Parkinson's disease. Their caregivers are specially trained to handle the unique needs of individuals facing mobility challenges, communication difficulties, and emotional changes associated with the condition.
Services offered include: Mobility and transfer assistance
Medication reminders
Personal hygiene and grooming support
Meal preparation and light housekeeping
Emotional support and companionship
Visiting Angels Manassas develops customized care plans tailored to each client's stage of Parkinson's and personal preferences. By promoting safety, routine, and emotional well-being, they help individuals remain in the comfort of their own homes while receiving professional, compassionate care.
While physical symptoms often take center stage, emotional health plays a critical role in daily living for people with Parkinson's. Many experience depression, anxiety, or frustration as they lose independence and struggle to perform everyday tasks.
Caregivers can help by offering companionship, engaging conversation, and encouragement throughout the day. They may also guide clients through light cognitive activities such as puzzles, reading or therapy that stimulate the brain and provide mental engagement.
This emotional support not only improves mood but can also slow cognitive decline and promote a more positive outlook.
aring for a loved one with Parkinson's is often a full-time responsibility. The physical demands, emotional stress, and unpredictability of symptoms can quickly lead to caregiver burnout. This can compromise not only the caregiver's well-being but also the quality of care they're able to provide.
Professional home care offers families much-needed relief. Whether through daily visits or occasional respite care, trained caregivers allow family members time to rest, attend to personal matters, or simply recharge. This shared responsibility ensures long-term sustainability of care and helps preserve strong family relationships.
Care providers also offer education and guidance, helping families better understand Parkinson's progression and how to communicate effectively with their loved one.
Specialized home care for people with Parkinson's is about more than just physical help it's about preserving independence, promoting dignity, and maintaining quality of life at every stage of the disease. With expert assistance, individuals can remain safe and supported in the comfort of their own home while families gain peace of mind.
From managing medications and improving mobility to offering emotional support and caregiver relief, Parkinson's home care covers all the key areas needed for a better daily life. For families in Prince William County and nearby areas, Visiting Angels provides the personalized, reliable care needed to face Parkinson's with confidence.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
6 hours ago
- Time Business News
How Specialized Parkinson's Home Care Improves Daily Living
Parkinson's disease is a progressive neurological condition that affects movement, balance, and coordination. As the disease advances, daily activities that once felt routine—such as walking, eating, or getting dressed—can become difficult and even dangerous. While family members often try to help, the increasing demands of care may require professional support. Specialized home care tailored for individuals with Parkinson's offers critical physical, emotional, and cognitive assistance, helping improve daily living and quality of life. In this article, we'll explore how Parkinson's home care works, its benefits, and how trusted providers like Visiting Angels Manassas support families across Prince William County and surrounding areas. Parkinson's disease primarily affects motor function, resulting in symptoms such as tremors, muscle stiffness, slowness of movement (bradykinesia), and impaired balance. These symptoms often interfere with simple daily tasks like writing, using utensils, or getting out of a chair. As the condition progresses, walking becomes more difficult and falls more likely. However, Parkinson's is not just a physical condition. Non-motor symptoms such as depression, sleep disturbances, fatigue, and cognitive decline can be just as challenging. Over time, these symptoms can diminish confidence and increase dependency on others for daily support. This combination of physical and emotional impact often leads families to seek long-term solutions that maintain safety and well-being at home. One of the most significant benefits of specialized home care is assistance with mobility and physical safety. Individuals with Parkinson's often experience unsteadiness, slower reflexes, and difficulties with balance. This greatly increases the risk of falls, which can lead to serious injuries. Professional caregivers trained in Parkinson's care know how to assist with transferring from bed to chair, walking around the house, and using assistive devices properly. They are also skilled in spotting mobility-related hazards and suggesting modifications like grab bars, shower benches, or the removal of clutter. For families seeking Parkinson's care in Manassas these services provide critical support in maintaining independence while minimizing physical risks. Proper medication management is vital for those living with Parkinson's. Medications like Levodopa must be taken at specific times to manage symptoms effectively. A missed or late dose can quickly result in loss of motor control or increased stiffness. Home caregivers ensure medications are taken on schedule and watch for any adverse effects or symptom changes. They also assist with daily routines such as eating, bathing, grooming, and dressing, tasks that become more complex as the disease progresses. The consistency and reliability of professional care allow individuals to maintain a sense of control and routine, which is especially important for people with Parkinson's who thrive on structure. For families in Prince William County and surrounding communities, Visiting Angels Manassas is a trusted provider of in-home care services for seniors with Parkinson's disease. Their caregivers are specially trained to handle the unique needs of individuals facing mobility challenges, communication difficulties, and emotional changes associated with the condition. Services offered include: Mobility and transfer assistance Medication reminders Personal hygiene and grooming support Meal preparation and light housekeeping Emotional support and companionship Visiting Angels Manassas develops customized care plans tailored to each client's stage of Parkinson's and personal preferences. By promoting safety, routine, and emotional well-being, they help individuals remain in the comfort of their own homes while receiving professional, compassionate care. While physical symptoms often take center stage, emotional health plays a critical role in daily living for people with Parkinson's. Many experience depression, anxiety, or frustration as they lose independence and struggle to perform everyday tasks. Caregivers can help by offering companionship, engaging conversation, and encouragement throughout the day. They may also guide clients through light cognitive activities such as puzzles, reading or therapy that stimulate the brain and provide mental engagement. This emotional support not only improves mood but can also slow cognitive decline and promote a more positive outlook. aring for a loved one with Parkinson's is often a full-time responsibility. The physical demands, emotional stress, and unpredictability of symptoms can quickly lead to caregiver burnout. This can compromise not only the caregiver's well-being but also the quality of care they're able to provide. Professional home care offers families much-needed relief. Whether through daily visits or occasional respite care, trained caregivers allow family members time to rest, attend to personal matters, or simply recharge. This shared responsibility ensures long-term sustainability of care and helps preserve strong family relationships. Care providers also offer education and guidance, helping families better understand Parkinson's progression and how to communicate effectively with their loved one. Specialized home care for people with Parkinson's is about more than just physical help it's about preserving independence, promoting dignity, and maintaining quality of life at every stage of the disease. With expert assistance, individuals can remain safe and supported in the comfort of their own home while families gain peace of mind. From managing medications and improving mobility to offering emotional support and caregiver relief, Parkinson's home care covers all the key areas needed for a better daily life. For families in Prince William County and nearby areas, Visiting Angels provides the personalized, reliable care needed to face Parkinson's with confidence. TIME BUSINESS NEWS
Yahoo
8 hours ago
- Yahoo
BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress
CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) ('BioVie' or the 'Company') a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in poster session at the upcoming Advanced Therapeutics in Movement & Related Disorders® Congress, to be held at National Harbor, MD, from June 27 to June 30, 2025. Details for the poster session are as follows: Title: SUNRISE-PD: An Ongoing, Hybrid, Decentralized Phase 2 Study of Bezisterim (NE3107) in Early Parkinson's DiseasePoster session: 11:30am to 12:30pm, Friday June 27Authors: Mark Stacy; Clarence Ahlem; Christopher L. Reading; Jeffrey Zhang; Joseph M. PalumboPoster position: P 49Poster displayed from 7:00am Friday June 27 through 2:00pm Sunday June 29 SUNRISE-PD is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial with a hybrid decentralized design that will last 20 weeks from the initial screening phase to the safety follow up. As part of the trial, patients may participate either completely from their home or at a clinical site. At-home participants will be visited by study nurses who will complete study assessments with the assistance of a neurologist who will attend the visit remotely by video and supervise administration of a modified MDS-UPDRS Part III examination, which will be recorded for review and scoring by a central rating committee. If the trial's results are positive, participants may be eligible to enter a longer-term, open-label safety study. About Parkinson's Disease Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects movement. It is characterized by the loss of dopamine-producing neurons in the substantia nigra, a region of the brain critical for motor control. Core symptoms include tremors, muscle rigidity, bradykinesia (slowness of movement), postural instability, and difficulties with speech.1-2 Non-motor symptoms, such as cognitive impairment, mood disorders, and autonomic dysfunction, also significantly impact patients' quality of life.3 In the early stages, symptoms are often mild and may include subtle tremors, slight movement difficulties, and changes in handwriting or facial expressions. As the disease progresses, motor symptoms become more pronounced, leading to difficulties with balance, speech, and daily activities, often requiring full-time care in later stages.4 Since the 1960s, when dopamine's critical role in Parkinson's disease was first identified, levodopa has remained the cornerstone of treatment, providing significant symptom relief by replenishing dopamine levels in the brain.5-6 However, long-term use is associated with complications such as motor fluctuations—where symptom control becomes less stable—and dyskinesia, involuntary movements that can become debilitating.7-9 Emerging research highlights the role of chronic inflammation and insulin resistance in the onset and progression of Parkinson's disease. Neuroinflammation, driven by activated microglia and elevated levels of pro-inflammatory cytokines, contributes to oxidative stress and accelerates neuronal degeneration.10-12 Additionally, insulin resistance, which impairs the brain's ability to regulate glucose metabolism, has been linked to increased neurodegeneration and worsening motor symptoms.13-14 These metabolic dysfunctions create a harmful cycle that exacerbates disease progression, underscoring the potential of anti-inflammatory and insulin-sensitizing therapies as new avenues for treatment. About Bezisterim Bezisterim (NE3107) is an orally bioavailable, blood-brain barrier (BBB)-permeable modulator of inflammation and insulin-sensitizer. In addition, it is not immunosuppressive and has a low risk of drug-drug interaction. By binding to ERK and selectively modulating NFκB activation and TNF-α production, BioVie believes that bezisterim may offer clinical improvements in several disease indications, including Alzheimer's disease, Parkinson's disease and long COVID. In Parkinson's disease, BioVie is currently enrolling patients in the Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim on motor and non-motor symptoms in patients who have not been treated with carbidopa/levodopa, with topline data expected in late 2025 or early 2026. A previous Phase 2 study of bezisterim in Parkinson's disease (NCT05083260) completed in 2022, and data presented at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Gothenburg, Sweden in March 2023 showed significant improvements in 'morning on' symptoms and clinically meaningful improvement in motor control in patients treated with a combination of bezisterim and levodopa versus patients treated with levodopa alone, and no drug-related adverse events. In long COVID, bezisterim has the potential to reduce neurological symptoms including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFκB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg). BioVIe's Phase 2 ADDRESS-LC study, is a randomized (1:1), placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety, tolerability and potential efficacy of 3 months of treatment with bezisterim to reduce the neurocognitive symptoms associated with long COVID, including difficulty concentrating or remembering things ('brain fog') and fatigue. In Alzheimer's disease, BioVie conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate Alzheimer's disease (NCT04669028) in 2023. Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's disease. About BioVie Inc. BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-κB, and the associated neuroinflammation and insulin resistance but not ERK and NFκB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit Forward-Looking Statements This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. References 1 Cleveland Clinic. Parkinson's Disease. Last reviewed: 2022 Apr 15.2 Jankovic J. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.3 Postuma RB, Berg D, Stern M, et al. Mov Disord. 2015;30(12):1591-1601.4 Kalia LV and Lang AE. Lancet. 2015;386(9996):896-912.5 Hornykiewicz O. Angew Chem Int Ed. 2002;41(17):2934-2941.6 Olanow CW, Obeso JA and Stocchi F. Lancet Neurol. 2006;5(8):677-687.7 Ahlskog JE and Muenter MD. Mov Disord. 2001;16(3):448-458.8 Espay AJ, Morgante F, Merola A, et al. Ann Neurol. 2018;84(6):797-811.9 Cilia R and Akpalu A. J Neural Transm. 2020;127(5):889-916.10 Jurcau A, Andronie-Cioara FL, Nistor-Cseppento DC, et al. Int J Mol Sci. 2023;24:14582.11 Pajares M, Rojo AI, Manda G, et al. Cells. 2020;9:1687.12 Isik S, Kiyak BY, Akbayir R, et al. Cells. 2023;12:1012.13 Zagare A, Hemedan A, Almeida C, et al. Mov Disord. 2025;40(1):67-76.14 Ruiz-Pozo VA, Tamayo-Trujillo R, Cadena-Ullauri S, et al. Nutrients. 2023;15(16): Chuck Padala Managing Director LifeSci Advisors, LLC chuck@ Melyssa WeibleManaging Partner, Elixir Health Public Relations Ph: +1 201-723-5705mweible@
Newsweek
15 hours ago
- Newsweek
Your Ear Wax Can Reveal if You Have Parkinson's Disease
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The levels of the natural bodily oil sebum in ear wax could be used to detect Parkinson's disease early, according to a new study. Changes in sebum have previously been linked with the neurodegenerative disorder, with those with the condition having sebum that gives off a characteristic smell. Furthermore, volatile organic compounds (VOCs) released by sebum are impacted by processes involved in the progression of Parkinson's, including neurodegeneration, oxidative stress and systemic inflammation. The stumbling block to making use of this information, however, has been than environmental factors like air pollution and humidity can also affect the composition of sebum, meaning that sampling from the skin may not provide reliable information. To get around this, chemists Hao Dong, Danhua Zhu and colleagues turned to ear wax—which can both be easily sampled but, coming from the skin in the ear canal, is protected from environmental alteration. A stock image of a woman using a cotton swab on her ear. A stock image of a woman using a cotton swab on her ear. fizkes/Getty Images In their study, the researchers collected ear wax samples from 209 people–108 of whom have received a Parkinson's diagnosis—and analyzed their composition using gas chromatography and mass spectrometry. Four of the VOCs detected in the ear wax of those with Parkinson's disease were found to significantly different to the VOCs in healthy subjects. (Specifically, the study concluded that ethylbenzene, 4-ethyltoluene, pentanal and 2-pentadecyl-1,3-dioxolane are potential biomarkers for Parkinson's disease.) Next, the team trained an artificial intelligence olfactory system to analyze VOC data. This system was able to categorize ear wax samples with 94 percent accuracy, with the researchers saying this could lead to a first-line screening tool for early-onset Parkinson's. Dong said: "This method is a small-scale single-center experiment in China. The next step is to conduct further research at different stages of the disease, in multiple research centers and among multiple ethnic groups, in order to determine whether this method has greater practical application value." Parkinson's disease is the second-most common neurodegenerative disorder in the U.S, after Alzheimer's disease. Symptoms of the condition include tremors, slow movement, stiffness and impaired balance—given Parkinson's progressive nature, these conditions gradually and increasingly impact a person's ability to walk, talk and swallow. Approximately 500,000 Americans are diagnosed with Parkinson's disease, most of whom are over the age of 60. However, it's thought that many people go undiagnosed for years. Indeed, some experts have suggested that as many as one million Americans could have the condition, according to the National Institute of Neurological Disorders and Stroke. The cost of treating Parkinson's disease is an estimated $14 billion each year—and with the number of diagnoses expected to double in the U.S. by 2040, early detection is key. Current testing methods typically entail clinical rating scales and neural imaging, but screening for the disease with ear wax samples could be relatively inexpensive in comparison, the ACS suggests. At present, most treatments can only slow the disease progression rather than curing it, but an earlier diagnosis could offer a window to prevent the progression prior to the onset of motor impairments. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about Parkinson's? Let us know via health@ Reference Chen, X., Li, Y., Pan, C., Weng, S., Xie, X., Zhou, B., Dong, H., & Zhu, D. (2025). An Artificial Intelligence Olfactory-Based Diagnostic Model for Parkinson's Disease Using Volatile Organic Compounds from Ear Canal Secretions. Analytical Chemistry, 97(24), 12633–12641.
